World Journal of Surgery

, Volume 35, Issue 7, pp 1590–1595 | Cite as

Survival After Liver Transplantation Using Hepatitis C Virus-Positive Donor Allografts: Case-Controlled Analysis of the UNOS Database

  • Andrew T. Burr
  • YouFu Li
  • Jennifer F. Tseng
  • Reza F. Saidi
  • Adel Bozorgzadeh
  • Shimul A. Shah



Numerous reports have documented reduced graft and patient survival after use of hepatitis C (HCV) seropositive allografts in liver transplantation (OLT). We aimed to examine if the use of a HCV+ liver allograft affects patient and graft survivals compared to HCV− donor allografts in a case-controlled analysis of the united network for organ sharing (UNOS) database.


We examined 63,149 liver transplants (61,905 donors HCV−; 1,244 donors HCV+) from the UNOS standard transplant analysis and research (STAR) file from 1987 to 2007. Donor and recipient demographics and outcomes were collected in which donor HCV serology was complete. A case-controlled cohort from 11 donor and recipient variables comparing donor HCV− and HCV+ allografts (n = 540 in each group) was created using propensity scores with a matching algorithm. Graft and patient survival was estimated using Kaplan–Meier survival curves.


Significant differences were evident in the unadjusted cohort between recipients who received HCV+ and HCV− allografts, including HCV+ recipients, donor and recipient age, and model for end-stage liver disease (MELD) exception cases. Use of HCV+ allograft resulted in significantly lower graft survival (8.1 vs. 10.6 years; P = 0.001) and patient survival (10.2 vs. 12.3 years; P = 0.01) after OLT. In the matched cohort, HCV seropositivity had no detrimental effect on the graft (P = 0.57) or patient (P = 0.78) survival after OLT.


This is the first population-based analysis to show that after adjusting for donor and recipient characteristics there was no difference in graft or patient survival with the use of HCV+ donor liver allografts compared to HCV− donor liver allografts.


  1. 1.
    United Network for Organ Sharing (2009) Transplant patient data source. Available at Accessed 19 Aug 2009
  2. 2.
    Pereira B, Milford E, Kirkman R (1992) Prevalence of HCV RNA in hepatitis C antibody positive cadaver organ donors and their recipients. N Engl J Med 327:910–915PubMedCrossRefGoogle Scholar
  3. 3.
    Dominguez-Gil B, Morales JM (2009) Transplantation in the patient with hepatitis C. Transplant Int 22:1117–1131CrossRefGoogle Scholar
  4. 4.
    Rubin D (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757–763PubMedGoogle Scholar
  5. 5.
    Austin P, Grootendorst P, Normand SL et al (2007) Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Stat Med 26:754–768PubMedCrossRefGoogle Scholar
  6. 6.
    Khapra AP, Agarwal K, Fiel MI et al (2006) Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 12:1496–1503PubMedCrossRefGoogle Scholar
  7. 7.
    Ghobrial RM, Seadman R, Gornbein J et al (2001) A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 234:384–394PubMedCrossRefGoogle Scholar
  8. 8.
    Terrault NA, Shiffman ML, Lok AS et al (2007) Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 13:122–129PubMedCrossRefGoogle Scholar
  9. 9.
    Vargas HE, Laskus T, Wang LF et al (1999) Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 117:149–153PubMedCrossRefGoogle Scholar
  10. 10.
    Testa G, Vidanovic V, Chejfec G et al (2008) Adult living-donor liver transplantation with ABO-incompatible grafts. Transplantation 85:681–686PubMedCrossRefGoogle Scholar
  11. 11.
    Velidedeoglu E, Desai NM, Campos L et al (2002) The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 73:582–587PubMedCrossRefGoogle Scholar
  12. 12.
    Axelrod D, Schnitzler M, Salvalaggio PR et al (2007) The economic impact of the utilization of liver allografts with high donor risk index. Am J Transpl 7:990–997CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2011

Authors and Affiliations

  • Andrew T. Burr
    • 1
  • YouFu Li
    • 1
  • Jennifer F. Tseng
    • 1
  • Reza F. Saidi
    • 1
  • Adel Bozorgzadeh
    • 1
  • Shimul A. Shah
    • 1
    • 2
  1. 1.Department of Surgery, Surgical Outcomes Analysis & ResearchUniversity of Massachusetts Medical SchoolWorcesterUSA
  2. 2.Solid Organ Transplantation, Department of SurgeryUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations